Roche's Lucentis Could Get Boost From House Compounding Directives To FDA
This article was originally published in The Pink Sheet Daily
Compounding pharmacies – and makers of particular products – would see favorable guidance changes under instructions to FDA in House appropriations report.
You may also be interested in...
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Pink Sheet reporters and editor discuss the new monkeypox vaccine EUA, the potential impact of drug pricing legislation, and how things may have been different if the FDA already had a desired technology upgrade.